Simona King - 18 Apr 2023 Form 4 Insider Report for Passage BIO, Inc. (PASG)

Role: Chief Financial Officer
Signature: /s/ Edgar Cale, Attorney-in-Fact
Issuer symbol: PASG
Transactions as of: 18 Apr 2023
Net transactions value: -$2,156
Form type: 4
Filing time: 20 Apr 2023, 16:28:49 UTC
Previous filing: 05 Apr 2023
Next filing: 01 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PASG	Common Stock	Options Exercise	$0	+6,250		$0.000000	6,250	18 Apr 2023	Direct	F1
transaction	PASG	Common Stock	Sale	$2,156	-2,053	-50%	$1.05	2,053	18 Apr 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PASG	Restricted Stock Units	Options Exercise	$0	-6,250	-25%	$0.000000	18,750	18 Apr 2023	Common Stock	6,250		Direct	F1, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2	The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
F3	1/4 of the RSUs vested on April 18, 2023, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F4	These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.